XTX 501
Alternative Names: PD1/IL2-ACT - Xilio Therapeutics; PD1/IL2-advanced cytokine therapy - Xilio Therapeutics; XTX-501Latest Information Update: 20 Jun 2024
Price :
$50 *
At a glance
- Originator Xilio Therapeutics
- Class Antineoplastics
- Mechanism of Action Interleukin 2 receptor agonists; Programmed cell death-1 ligand-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Adverse events, pharmacokinetics and pharmacodynamics data from preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 14 Apr 2023 Preclinical trials in Cancer in USA (Parenteral)
- 14 Apr 2023 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical trial in Cancer presented 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)